Analyst Reco. Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-03-13 pm EDT			5-day change	1st Jan Change
59.08 ^USD	+0.22%		-2.01%	+9.53%

Mar. 13	Health Rounds: Eliquis proves safer than Xarelto for patients with deep blood clots	RE
Mar. 10	BioNTech founders plan exit to set up new venture, shares slump	RE

Analyst Reco.

Mar. 09	Global markets live: Live Nation, Eli Lilly, Amazon, Microsoft, ABB…
Feb. 25	Bristol-Myers Squibb's Risk/Reward Profile Balanced, RBC Says	MT
Feb. 25	RBC Initiates Bristol-Myers Squibb at Sector Perform With $60 Price Target	MT
Feb. 25	Berenberg Lifts Price Target on Bristol-Myers Squibb to $60 From $57, Keeps Hold Rating	MT
Feb. 23	Piper Sandler Adjusts Price Target on Bristol-Myers Squibb to $75 From $66, Maintains Overweight Rating	MT
Feb. 20	Daiwa Securities Adjusts Price Target on Bristol-Myers Squibb to $62 From $43, Maintains Neutral Rating	MT
Feb. 20	Analyst recommendations: Walmart, Alphabet, Deere & Company, Stellantis, Workday…
Feb. 06	Wells Fargo Adjusts Bristol-Myers Squibb PT to $60 From $55, Maintains Equal Weight Rating	MT
Feb. 06	Citigroup Adjusts Bristol-Myers Squibb PT to $64 From $60, Maintains Neutral Rating	MT
Feb. 06	JPMorgan Adjusts Bristol-Myers Squibb PT to $67 From $65, Maintains Overweight Rating	MT
Feb. 06	Morgan Stanley Lifts Price Target on Bristol-Myers Squibb to $40 From $37, Keeps Underweight Rating	MT
Feb. 06	Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $61 From $57, Maintains Neutral Rating	MT
Feb. 06	Leerink Partners Adjusts Price Target on Bristol-Myers Squibb to $67 From $60, Maintains Outperform Rating	MT
Feb. 06	Guggenheim Raises Price Target on Bristol-Myers Squibb to $72 From $62, Maintains Buy Rating	MT
Feb. 05	JPMorgan Raises Bristol-Myers Squibb Price Target to $67 From $65	MT
Jan. 29	TD Cowen Adjusts Bristol-Myers Squibb Price Target to $60 From $54, Maintains Hold Rating	MT
Jan. 28	Piper Sandler Adjusts Bristol-Myers Squibb Price Target to $66 From $62, Maintains Overweight Rating	MT
Jan. 27	Citigroup Adjusts Price Target on Bristol-Myers Squibb to $60 From $53, Maintains Neutral Rating	MT
Jan. 26	BMO Capital Adjusts PT on Bristol-Myers Squibb to $55 From $47, Maintains Market Perform Rating	MT
Jan. 13	Leerink Partners Adjusts Price Target on Bristol-Myers Squibb to $60 From $54, Maintains Outperform Rating	MT
Jan. 09	Scotiabank Adjusts Price Target on Bristol-Myers Squibb to $60 From $53, Maintains Sector Perform Rating	MT
Jan. 07	UBS Upgrades Bristol-Myers Squibb to Buy From Neutral, Lifts Price Target to $65 From $46	MT
Dec. 17	Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $65 From $52, Maintains Hold Rating	MT
Dec. 15	Bristol-Myers Squibb Seen as Attractive Ahead of 2026 Pipeline Catalysts, BofA Says	MT
Dec. 15	BofA Securities Upgrades Bristol-Myers Squibb to Buy From Neutral, $61 Price Target	MT